TY - JOUR
T1 - Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
AU - Slingluff, Craig L.
AU - Lewis, Karl D.
AU - Andtbacka, Robert
AU - Hyngstrom, John
AU - Milhem, Mohammed
AU - Markovic, Svetomir N.
AU - Bowles, Tawnya
AU - Hamid, Omid
AU - Hernandez-Aya, Leonel
AU - Claveau, Joel
AU - Jang, Sekwon
AU - Philips, Prejesh
AU - Holtan, Shernan G.
AU - Shaheen, Montaser F.
AU - Curti, Brendan
AU - Schmidt, William
AU - Butler, Marcus O.
AU - Paramo, Juan
AU - Lutzky, Jose
AU - Padmanabhan, Arvinda
AU - Thomas, Sajeve
AU - Milton, Daniel
AU - Pecora, Andrew
AU - Sato, Takami
AU - Hsueh, Eddy
AU - Badarinath, Suprith
AU - Keech, John
AU - Kalmadi, Sujith
AU - Kumar, Pallavi
AU - Weber, Robert
AU - Levine, Edward
AU - Berger, Adam
AU - Bar, Anna
AU - Beck, J. Thaddeus
AU - Travers, Jeffrey B.
AU - Mihalcioiu, Catalin
AU - Gastman, Brian
AU - Beitsch, Peter
AU - Rapisuwon, Suthee
AU - Glaspy, John
AU - McCarron, Edward C.
AU - Gupta, Vinay
AU - Behl, Deepti
AU - Blumenstein, Brent
AU - Peterkin, Joanna J.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2021.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Background Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here. Methods Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients. Results For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients <60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952)). Conclusions Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas. Trial registration number NCT01546571.
AB - Background Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here. Methods Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients. Results For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients <60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952)). Conclusions Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas. Trial registration number NCT01546571.
KW - active
KW - immunotherapy
KW - melanoma
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=85116665868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116665868&partnerID=8YFLogxK
U2 - 10.1136/jitc-2021-003272
DO - 10.1136/jitc-2021-003272
M3 - Article
C2 - 34599031
AN - SCOPUS:85116665868
SN - 2051-1426
VL - 9
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 10
M1 - e003272
ER -